Effectiveness of Myopia Control Interventions : A Comparison of Myopia Control in European Children, Adolescents and Young Adults With Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL) Spectacles, Atropine, Lenses and Combined Treatments

NCT07120165 | Completed

• 1 other identifier: IRBN1022025/CHUSTE
• Study Type: observational
• Target: 114
• Locations: 1 country
• Sites: 1

Brief Summary

The prevalence of myopia and its complications has risen considerably in recent decades, particularly among children and teenagers. This trend is also spreading in Europe, driven by the increase in screen time and the intensive use of new technologies and social media, particularly among the younger generation. Several treatment options are available today, including pharmacological treatments with atropine eye drops, as well as optical myopia control systems in the form of glasses or contact lenses. These different treatments have been used in clinical practice at Saint-Étienne University Hospital since 2017 for atropine, and more recently with the development of optical myopia control systems and their combinations. Little clinical data has been published to date on these different treatment combinations in the French population. The investigators would therefore like to set up a database to publish their results and share their experience.

Conditions

Myopia

Keywords

Myopia; children; teenagers; atropine; lunettes; contact lenses; combinations

Outcome Measures

Primary Outcomes (1)

• Database of active treatments for myopia

  Database established with data from children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control spectacles or contact lenses, and their various combinations.

  Month 5

Study Arms (3)

Atropine 0.01%

Children or young adults with active myopia treated with ATROPINE 0.01% eye drops.

Other: Demographic data collection; Other: Ophthalmological history; Other: Ophthalmological data at each examination; Other: Potential adverse events

DIMS/HAL

Children or young adults with active myopia treated with myopia control glasses.

Other: Demographic data collection; Other: Ophthalmological history; Other: Ophthalmological data at each examination; Other: Potential adverse events

Various combined treatments

Children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control glasses or contact lenses, and their various combinations.

Other: Demographic data collection; Other: Ophthalmological history; Other: Ophthalmological data at each examination; Other: Potential adverse events

Interventions

Demographic data collection OTHER

Demographic data collection: age, gender, level of education/study, time spent in near vision, sports practice, medical history

Atropine 0.01%; DIMS/HAL; Various combined treatments

Ophthalmological history OTHER

Ophthalmological history: age of myopia discovery, parental refraction, previous refractions, presence of a braking treatment

Atropine 0.01%; DIMS/HAL; Various combined treatments

Ophthalmological data at each examination OTHER

Ophthalmological data at each examination: visual acuity, subjective refraction, cycloplegia with SKIACOL, axial length.

Atropine 0.01%; DIMS/HAL; Various combined treatments

Potential adverse events OTHER

Potential adverse events: halos, photophobia, stinging, infections, etc.

Atropine 0.01%; DIMS/HAL; Various combined treatments

Eligibility Criteria

• Age: Up to 25 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control glasses or contact lenses, and their various combinations will be included.

You may qualify if:

• Children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control glasses or contact lenses, and their various combinations
• patient affiliated with a social security organization
• agreement of both parents or the patient if adult

You may not qualify if:

• \- non compliance with treatment

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Saint Etienne: lead

Study Sites (1)

CHU de Saint-Étienne

Saint-Etienne, 42100, France

Location

MeSH Terms

Conditions

Myopia

Condition Hierarchy (Ancestors)

Refractive Errors; Eye Diseases

Study Officials

• Marie-Caroline TRONE, Md

  CHU de Saint-Étienne

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 6, 2025
• First Posted: August 13, 2025
• Study Start: October 20, 2024
• Primary Completion: May 7, 2025
• Study Completion: May 7, 2025
• Last Updated: August 13, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)